Arxada AG, a global specialty chemicals business, is investing CHF 20 million ($21.6 million) in its industrial biotechnological plant in Kouřim, Czech Republic, which serves the contract development and manufacturing organization (CDMO) part of its Specialty Products Solutions business.   This investment provides important infrastructure debottlenecking in connection with expanded technological options and the addition of significant formulation capacity necessitated by Arxada’s growing custome...